Antibacterial dressing for promoting scarless healing of wound surface and method for preparing the same
US-2024350702-A1 · Oct 24, 2024 · US
US10098982B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10098982-B2 |
| Application number | US-201415036822-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 20, 2014 |
| Priority date | Nov 20, 2013 |
| Publication date | Oct 16, 2018 |
| Grant date | Oct 16, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention describes methods and compositions of hydrogel microspheres for inducing macrophage conversion by sequentially converting a first population of wound macrophages in a wound to M2A macrophages by exposing the first population of wound macrophages to IL-4 and converting a second population of wound macrophages to M2C macrophages by exposing the second population of wound macrophages to IL-10. One aspect describes a method of inducing macrophage conversion in a wound. Another aspect describes compositions and methods of preparing a hydrogel microsphere for wound healing. Yet another aspect describes methods for treating a chronic wound with hydrogel microspheres.
Opening claim text (preview).
What is claimed is: 1. A method of inducing macrophage conversion in a wound comprising sequentially inducing conversion of a first population of wound macrophages in the wound to M2A macrophages and then converting a second population of wound macrophages in the wound to M2C macrophages, wherein inducing conversion of the macrophages comprises: applying hydrogel microspheres to the wound, wherein the hydrogel microspheres comprise: an inner core of hydrogel polymers bound to one or more selected from the group consisting of: interleukin-10 (IL-10), dexamethasone, and a dexamethasone analog; and an outer shell of hydrogel polymers bound to interleukin-4 (IL-4); inducing conversion of the first population of wound macrophages in the wound to M2A macrophages by exposure to the IL-4 that is released from the outer shell of the hydrogel microspheres; and then inducing conversion of the second population of wound macrophages to M2C macrophages by exposure to the IL-10, dexamethasone, or the dexamethasone analog that is released from the inner core of the hydrogel microspheres. 2. The method of claim 1 , wherein the inner core of hydrogel polymers is bound to interleukin-10 (IL-10) ; and conversion of the second population of wound macrophages to M2C macrophages is induced by exposure to IL-10 that is released from the inner core of the hydrogel microspheres. 3. The method of claim 1 , wherein: the inner core of hydrogel polymers is bound to dexamethasone or a dexamethasone analog, and conversion of the second population of wound macrophages to M2C macrophages is induced by exposure to the dexamethasone or the dexamethasone analog that is released from the inner core of the hydrogel microspheres. 4. The method of claim 3 , wherein the inner core of hydrogel polymers is bound to dexamethasone. 5. The method of claim 1 , wherein: the IL-10 is released by enzymatic cleavage by an enzyme that is present in the wound and the enzyme comprises a matrix metalloprotease that cleaves the IL-10 from the polymer. 6. The method of claim 1 , wherein the IL-10 is released by degradation of the hydrogel polymer. 7. The method of claim 1 , further comprising wherein when the macrophage conversion in the wound occurs, the wound is treated. 8. The method of claim 1 , wherein the wound is a chronic wound. 9. The method of claim 1 , wherein: the inner core of hydrogel polymers is bound to one or more selected from the group consisting of: interleukin-10 (IL-10) and dexamethasone; and conversion of the second population of wound macrophages to M2C macrophages is induced by exposure to IL-10 or dexamethasone that is released from the inner core of the hydrogel microspheres.
Immunomodulating agents, i.e. cytokines, interleukins, interferons · CPC title
Alginic acid; Derivatives thereof · CPC title
Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines · CPC title
IL-10 · CPC title
Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.